Previous 10 | Next 10 |
Amryt Announces New Patent for Mycapssa® DUBLIN, Ireland, and Boston MA, May 11, 2022 Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, announces an upda...
Amryt Pharma PLC (AMYT) Q1 2022 Earnings Conference Call May 04, 2022, 08:30 ET Company Participants Simon Loughrey - Group Financial Controller Joseph Wiley - CEO & Director Rory Nealon - CFO, COO & Company Secretary Sheila Frame - President of Americas Tracy Cunningham - VP, Head of...
The following slide deck was published by Amryt Pharma plc in conjunction with their 2022 Q1 earnings call. For further details see: Amryt Pharma plc 2022 Q1 - Results - Earnings Call Presentation
Amryt Pharma press release (NASDAQ:AMYT): Q1 GAAP EPS of -$0.05. Revenue of $59.13M (+22.1% Y/Y). Given the continued strong performance of the Company’s commercial products, the board is today reaffirming revenue guidance for FY 2022 in the range of $260M - $270M which represents grow...
Amryt Reports Record Q1 2022 Results CHMP adopts positive opinion for Filsuvez® for the treatment of Dystrophic and Junctional EB Reaffirming FY 2022 revenue guidance to $260M - $270M, representing 17-21% YoY growth Board approve ...
A committee of the European Medicines Agency (EMA) recommended the approval of Amryt Pharma's (NASDAQ:AMYT) gel Filsuvez to treat a group of rare skin disorders called epidermolysis bullosa (EB). EB cause the skin to become fragile and any friction to the skin could c...
CHMP adopts positive opinion for Filsuvez® for the treatment of Dystrophic and Junctional EB Positive opinion based on largest ever pivotal global Phase 3 EASE study undertaken in EB Filsuvez® would be the first and only approved treatment in Europe for EB ...
A mryt to Report Q1 202 2 Results on May 4 , 2022 DUBLIN, Ireland, and Boston MA, April 14 , 202 2 , Amryt (Nasdaq: AMYT ) a global, commercial-stage biopharmaceutical company...
Amryt (NASDAQ:AMYT) reported long-term data from the 2nd year of the open-label extension phase (OLE) of its phase 3 trial evaluating Mycapssa versus placebo for maintenance of biochemical response in patients with acromegaly. Acromegaly is a disorder characterized by the pituitary gland prod...
Amryt Announces Positive Long-Term Safety and Efficacy Data for Mycapssa® (oral octreotide) from the 2 nd Year of OPTIMAL Open Label Extension Study in Acromegaly Patients Acromegaly patients were exposed to M ycapssa...
News, Short Squeeze, Breakout and More Instantly...
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases. Parma Italy, Dublin Ireland a...
Turnover at €2 billion 749 million, with growth of 13.6% over 2021 The European market remains at the center, with significant international development The distribution of turnover by therapeutic area is as follows: Air (respiratory diseases) 73%, Rare (rare and ultra-rare disease...
High Court of Justice of England and Wales Sanctions Scheme of Arrangement Acquisition of Amryt Pharma by Chiesi Farmaceutici Expected to Close Mid-April 2023 Dublin, Ireland, April 3 , 2023 Amryt Pharma Plc (“Amryt”) (Nasdaq...